Clinical trials: CNS Vasculitis
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis
- Trial name
- PRAVDA (NCT04280601)
- Testing
- vitamin D
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Christian Pagnoux
Giant Cell Arteritis
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
The aim of this study is to compare the use of FDG PET/CT to Ga-68 HA-DOTATATE (abbreviated DOTATATE) PET/CT in patients with active giant cell arteritis (GCA) started on prednisone to understand if DOTATATE can identify more…
- Trial name
- NCT03812302
- Testing
- 68-Ga HA-DOTATATE PET/CT
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University of Alberta
Autoimmune Diseases, Non-small Cell Lung Cancer
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis
- Trial name
- NCT03656627
- Testing
- Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases
Immunomodulatory Effects of PCSK9 Inhibition
Cardiovascular disease (CVD) represents the leading cause of death worldwide. While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also…
- Conditions
- Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation
- Trial name
- INSPIRAR (NCT05720156)
- Testing
- 99mTc-tilmanocept SPECT/CT scanning
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Giant Cell Arteritis
Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Giant Cell Arteritis (GCA) causes inflammation and narrowing of blood vessels and can cause blindness in one third of patients. It is important that a prompt, accurate diagnosis of GCA is made and treatment given as steroids for…
- Trial name
- TABUL (NCT00974883)
- Testing
- Ultrasound of temporal and axillary arteries, Temporal artery biopsy
- Where
- 27 sites in Germany, Ireland and 3 more
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
One-Time DNA Study for Vasculitis
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis
- Trial name
- NCT01241305
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Corticosteroid therapy has always been the standard treatment for giant cell arteritis (GCA), with very good initial clinical efficacy but a high relapse rate when it declines.
- Trial name
- CORTODOSE (NCT04012905)
- Testing
- Corticosteroids for Systemic Use
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
Systemic Lupus Erythematosus
Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus
The purpose of this study is to determine whether Libman-Sacks endocarditis (inflammation of the heart valves) is the cause of neuropsychiatric manifestations (stroke, transient ischemic attacks, cognitive dysfunction, seizures…
- Trial name
- NCT00858884
- Testing
- Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Arteritis, Giant Cell
Baricitinib in Relapsing Giant Cell Arteritis
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study.
- Trial name
- NCT03026504
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Matthew J Koster
Arteritis, Giant Cell, Blindness and Low Vision
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO
Giant cell arteritis , also named Horton's disease, is the most common vasculitis in subjects over 50 years old. The incidence increases with age : from 188 to 290 cases per million inhabitants per year, with a North-South…
- Trial name
- CECIBO (NCT03841734)
- Testing
- treatment
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Vasculitis, Systemic Vasculitis
Impact of Vasculitis on Employment and Income
The purpose of this study is to learn about the impact of vasculitis on employment and income in patients with different systemic vasculitides.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT02476292
- Testing
- online questionnaire
- Where
- United States
- Volunteers
- 426 people
- Sponsor
- University of South Florida
Giant Cell Arteritis (GCA)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA)…
- Trial name
- NCT07108387
- Testing
- Tocilizumab, Discontinue Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)